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Serum Ig M and IgG antibodies against Mycobacterhtm 
Jeprae-derived phenolic g lycolipid I (PG) were determined 
in le prosy patients, contacts, and controls b y enzyme-linked 
immunosorbent assay (ELISA). Anti-PG IgM levels in-
creased from the tuberculoid (TT) to the lepromatous (LL) 
po le of the disease spectrum . There was a positive linea r 
correlation between anu-PG Ig M and bacillary mdex (B I) . 
Patients with ery thema nodosum leprosum (ENL) had lower 
levels of serum anti-PG Ig M than non-ENL pati ents of 
comparable BI, sugges ting that anti-PG Ig M is invo lved 
in the pathogenesis of ENL. Initial observations indica te 
tha t hig h anti-PG Ig M levels in bacill ary-nega tive patients 
might reflect bacillary persisten ce. A study of 2 different 
substrate reagents in the ELISA [2 ,2 '-azino- di(3- eth yl-
benzthiazoline-6-sulfonic acid) (ABTS), 0.1 mM HzO~. 
serum diluted 1:20, and a-phenylenediamine (OPD), 5 mM 
T he mos t w idely used method for fo llowing disease act ivity and effect of trea tm ent in leprosy patients is to assess the load of Mycobacterirmr leprae by meas urin g the bacillary index (BI) in skin biopsies and sht smears. In recent yea rs, severa l advances in the serologic de-
tection of leprosy infections have been reported. Hunter et a] [I] 
have described a phenolic glycolipid I (PG) obtained from ar-
madillo-derived M. leprae containing an M. leprae-specific trisac-
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Abbreviations : 
ABTS: 2,2' -azino-di(3-cthyl-bcnzthiazoline-6-sulfonic acid) 
BB: midborderline leprosy 
Bl : b aci llary index 
BL: borderline lepromatous leprosy 
BSA: bovine serum albumin 
BT: borderline tuberculoid lep rosy 
ELISA : enzyme-linked immunosorbent assay 
ENL: erythema nodosum leprosum 
E: extinction 
H C: household contacts 
LL: lepromatous leprosy 
NC: nosocomial contacts 
OPD: o-phenylencdiamine 
PBS: phosphate-buffered saline 
PG: phenolic glycoli pid I 
TT: tuberculoid leprosy 
H 20 2, serum diluted 1 : 300] showed generall y good cor-
relation in de tection of anti-PG Ig M. H owever the OPD 
system detected more paucibacillary disease (BT), while 
the ABTS system d etected the sig nifi cant effect of ENL on 
the relationship between BI and anti-PG Ig M. Anti-PG 
IgM was clearly dominant over anti-PG IgG. However , 
certai n pati ents, including several pa tients who had up-
graded fro m LL and borderline lepromato us leprosy (BL), 
showed high levels of anti-PG IgG. Since studies have show n 
that LL patients are selectively deficient in cell-medi ated 
immunity, T - cell pro ducts m ay be required for the IgM 
to IgG isoty pe switch . We conclude that an ti-PG Ig M is 
useful for m o nito ring the bacillary load in individual pa-
tients and sh o uld prove useful for leprosy con trol strate-
gies. J Inv est Dermarol 86:529-534, 1986 
charide. Serum antibod ies against thi s g lycolipid in leprosy have 
been detected by immunodiffusion [2 ] and enzyme-linked im-
munosorbent assay (ELISA) techniques [1-4] . Serum levels of 
ant i-PG IgM predominating over anti-PG IgG [2,3] have been 
shown to increase from the tuberculoid (TT) toward the lepro-
matous (LL) pole of the disease spectrum [1-4]. Long-term trea t-
ment of lep rosy has been reported to result in a decrease in an-
tibodies to PG [2,3]. These results suggest a relationship between 
bacterial load and serum anti-PG Ig levels. 
In the current study we have developed a reprod ucible ELISA 
for detection of IgM and IgG antibodies to PG. In keeping with 
the work of others (1-4]. our stud y has shown a characteristi c 
pattern of ant i-PC lgM in patients grouped according to the Rid-
ley-Jopling class ifi ca tion [5]. In addition, by emphasizing clinical 
correlat ions, the current study has shown 4 additional findings 
that make antibodies aga inst PG es pecia ll y usefu l for moni toring 
leprosy patients. 
1. A direct co rrelation of an ti-PG IgM wi th the BI wi th some 
exceptions noted below. 
2. BI alone cannot accou nt for eleva ted anti-PG IgM va lues in 
LL and borderline lepromatous leprosy (BL). Significant 
anti-PG IgM levels eleva ted out of proportion to Bl were 
noted . Active neuropathies and recent elevated BI values 
suggested th at anti-PG lgM meas ured occulr bacill ary ac-
tivity, baci llary persistence undetected by biopsy, or anti-
genic persistence of PG. 
3. A decrease in the relationship between BI and anti-PG IgM 
(but not anti-PG lgG) with erythema nodosum leprosum 
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(ENL), suggested an involvement of anti-PG IgM in the 
pathogenesis of ENL. 
4. Finally, while anti-PG IgM predominates over anti-PG IgG, 
some patients develop good IgG responses . Initial obser-
vations indicate the lack of anti-PG IgG may be related to 
selective immune defects of lepromatous leprosy. 
MATERIALS AND METHODS 
Sera Leprosy patients were clinically and histologically classi-
fied according to the Ridley-Jopling scale IS]. The BI was mea-
sured on a semiquantitative scale (0-6 +) approximating that of 
Ridley [6]. Histology (including BI) was reported from the N a-
tional Hansen's Disease Center by 2 pathologists (C. K. Job, 
J. A. Freeman), whose agreement on BI was good (r = 0.94). 
Contacts ofleprosy patients consisted of household contacts (HC) 
and 14 nosocomial contacts (NC). Healthy subjects were used as 
normal controls. Serum samples were stored in aliquots at - 70°C. 
ELISA for Anti-PG IgM and IgG ELISA screening of sera 
for anti-PG Ig was performed w ith PG incorporated into lipo-
somes, as described for antibodies against g lycosphin golipids (7]. 
PG-Iiposomes were prepared as described by other authors (2]. 
PG (armadi llo-derived PG, kindly provided by P . J. Brennan), 
sphingomyelin , cholesterol, and dicetyl phosphate (0.1: 2.0:1.5: 0.2, 
molar ratjo) were combined in chlo roform-methanol 2:1 (v/v), 
the solvent was removed by rotary evaporation and the lipid 
mixture was sonicated (Branson Sonifier) in Tris-buffered saline 
{0.15 M NaCI, 20 mM Tris, pH 8.0) for 3 min {300 /-Lg PG/ml). 
Control liposomes without PG were prepared as above. Flat-
bottomed polystyrene microtiter plates (Dynatech) were coated 
by incubation with 100 ,.,_1 of the PG-Iiposome suspension (diluted 
to 2.5 /-Lg PG/ml in Tris-buffered saline), or with the control-
liposome suspension, for 18 hat 37°C. After washing (3 X) with 
phosphate-buffered saline (PBS) (0. 1 M phosphate buffer, pH 7. 2, 
0.15 M NaCI), plates were in cubated for 1.5 h at 3rC w ith 200 
ILl of 3% (w/v) bovine serum albumin (BSA, Sigma) in PBS 
(BSA-PBS). BSA-PBS was replaced by 100 ,.,_1 of test serum (in 
duplicate), diluted 1:20 in BSA-PBS. A positive lepromatous 
serum pool was included as reference on each plate. After incu-
bation with test serum for 1.5 h at 37°C, plates were again washed 
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with PBS (3 X ) and incubated for 1.5 hat 37°C with 100 ,ul of 
peroxidase-conjugated goat antih um an lgM o r IgG (Cappel) , di-
luted 1:1000 in BSA-PBS. After washing with PBS (3 x) 100 ,_,_1 
of substrate solution, containing 1.8 mM 2,2' -azino-di(3-echyl-
benzthiazoline-6-sulfonic acid) (ABTS) (Boehringer) and 0.1 m M 
H 20 2 in 0.1 M phosphate buffer pH 7.0, was added for 1 h at 
room temperature. The reaction was stopped with 100 ,ul of 
0 .32% (w/v) N aF and the extinction (E) was read at 405 nm using 
a Titerrek microtiter plate reader. The results were expressed as 
!:::.. E = E (PG-liposome coat) - E (control liposome coat). 
In o rder to compare our results with those of others (3], anti-
PG IgM levels were also determined by ELISA using an a-phen-
ylenediamine (OPD) substrate solution. The OPD ELISA pro-
cedure was identical to the ABTS ELISA with the followin g 
exceptions: ( I ) Sera were diluted 1 :300 in BSA-PBS. (2) The 
substrate solution contained 2.2 mM OPD (Sigm.a) and 5 m M 
H 20 2 in citrate phosphate buffer pH 5.0. (3) The reaction was 
stopped after 30 min with 100 ,..,_) 2 . 5 N H2S04 and absorbance 
read at 492 nm. 
Statistical Analysis Analysis was done by computer using 
BMDP statistica l packages (8]. Differences in anti-PG IgM and 
lgG levels among leprosy patients divided into Ridley-Jopling 
classes and controls were ascertained using analysis of variance 
with follow-up r-tests. In addition, because of the nonnormal 
distribution of !:::..E values, the data were also analyzed by the 
nonparametric Kruskal-Wallis test to confirm the analysis of var-
ian ce results . Differences in anti-PG IgM in Ridley-:Jopling groups 
and controls were also determined by analys is of variance using 
BI as covariate in order to determine whether factors other than 
BI contributed to hi gh anti-PG lgM in leprosy patients . 
Multiple correlations of lgM, lgG, and ENL were done with 
Bl as an independent variable using data from leprosy patients 
only to determine effects of E NL on the relationship between 
anti-PG IgM and BI , and anti-PG IgG and BI. 
RESULTS 
Experiments comparing techniques described by other authors 
for coating PG onto microtiter plates are shown in Fig 1. The 
most effective of these, PG in hexane, was compared with coating 
with PG incorporated into liposomes (Fig 2) . It can be seen that 
A. PG Sonicated in high pH buller B. PG in Sodium Deoxycholat e 
Figure 1. Comparison of 4 techniques for 
coating PG onto microtiter plates for ELISA. 
A, PG (100 !J.g/ml) suspended in ca rbonate-
bicarbonate buffer pH 9.6 by sonication, di-
luted to appropriate concentration, and in-
cubated in microtiter plates overnight at 37°C 
P1· B, PG (80 !J.g/ml) dissolved in PBS + 
0. 1% sodium deoxycholate, diluted to ap-
propriate concentrations, and incubated 
overnight at 37"C [2]. C a11d D , PG (10 
!J.glml) dissolved in hexane (C) or ethanol 
(D), diluted to appropriate concentrations, 
dispensed in microtiter plates and air-dried 
until so lvent evaporated [1] . 
E 
e = Lepromatous leprosy seru m ( 1/10 dil) 
0 = Normal human serum ( 11 tO) 
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Figure 2. Comparison of coating techniques using PG dissolved in hex-
ane and PG liposomcs . .& = PG-liposomcs; e = PG in hexane; broke11 
lines = control serum ( I : 10); solid li11es = lepromatous leprosy serum 
(I: 10) . 
greater antibody binding was obtained with PG liposomes than 
wi th PG in hexane. Optimal coating concentration for PG lip-
osomes was achieved by 2.5 J.Lg PG / ml, resulting in the most 
efficient utilization of limited PG supplies. 
Screening of sera from leprosy patients , contacts, and controls 
for anti-PG IgM antibodies revealed a characteristic pattern of 
anti-PG IgM in patients grouped according to the Ridley-Jopling 
classification. When the ELISA was performed using sera at 1 :20 
dilution and the ABTS substrate solution, the LL and BL groups 
had significantly elevated anti-PG IgM levels compared with con-
trols (p < 0.001, p < 0.05, respectively) by analysis of variance 
(Fig 3A). The nonparametric Kruskal-Wallis test indicated that 
LL, BL, midborderline leprosy (BB), and borderline tuberculoid 
leprosy (BT) groups were higher than controls (p < 0.05). Testing 
of HC and controls yielded one serum in each group with highly 
elevated ~E values for anti-PG lgM. Another serum sample was 
taken from the positive control 3 months after the initial bleeding 
which gave similar results. 
When sera were tested for anti-PG IgM at a 1 :300 dilution 
using the OPD substrate solution LL, BL, and BT groups were 
significantly higher than controls (p < 0.001, p < 0.01, p < 0.01, 
respectively) (Fig 3B). Nonparametric methods again showed LL, 
BL, BB, and BT groups to be higher than controls (p < 0.05). 
Correlation between .:lE values for the ABTS and OPD assays 
was good (r = 0.8038, p < 0.01). 
Anti-PG IgM in leprosy patients was found to increase with 
Bl when assayed with the ABTS (r = 0.5162, p < 0.01) and the 
OPD (r = 0.4409, p < 0.01) substrate solutions (Fig 4A,B). When 
all leprosy patients were used for analysis it was found that ENL 
had a significant effect on the relationship between BI and anti-
PG IgM, with ENL patients having lower levels of serum anti-
PG IgM than non-ENL patients of comparable Bl (Fig 4A , p = 






































































Figure 3. A , Anti-PG lgM levels vs Ridlcy-Jopling classification. Sera 
diluted I :20, ABTS substrate solution . B, Anti-PG IgM levels vs Ridley-
jopling classification. Sera diluted I : 300, OPD substrate solution. LL, 
lepromatous leprosy; BL, borderline lepromatous; BT, borderline tu-
berculoid; TT, tuberculoid leprosy; HC, household contacts ; NC, nos-
ocomial contacts ; Co11t, normal controls . 
0.0024). The effect of ENL on the relationship between anti-PG 
lgM and BI was apparent using the ABTS substrate solution, but 
not the OPD substrate solution, as the difference in the slopes of 
the regression lines for ENL and non-ENL patients did not reach 
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Figure 4. A, Effect of ENL on the relationship between BI and anti-PG 
IgM. Sera diluted I : 20, A BTS substrate solution. e = non-ENL patients, 
D = ENL more than 2 yea rs ago, /::; = ENL within the last 2 yea rs . B, 
Effect of ENL on the relationship between BI and anti-PG IgM. Sera 
diluted I :300, OPD substrate solution. 
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significance (p = 0.089) (Fig 48). The effect of ENL on the 
relationship between BI and anti- PG lgM was also seen when 
only BL and LL patients were used for anal ys is. With ABT S 
substrate solution and sera diluted 1:20, the regression line for 
Bl vs anti-PG IgM was significantly di fferen t for ENL patients 
as opposed to non-ENL patients. Again, with OPD and sera at 
1 :300 the effect of ENL on BI vs an ti-PG IgM was not seen 
(Table 1) . 
Although anti-PG lgM increased signifi cantly with increased 
BI , factors o ther than BI contribute to elevated anti-PG IgM levels 
in leprosy patients. A number of patients with BI = 0 are seen 
to have eleva ted anti-PG IgM (Fig 4A,B) . Statistica l analysis was 
performed to determine w hether factors other than BI signifi-
cantly contribute to anti-PG IgM levels in leprosy patients divided 
into Ridley-Jopling groups . Covariance ana lysis, using Bl as co-
variate determined that anti-PG IgM was signifi cantly elevated 
in leprosy patients due to fac tors other than Bl (Table II) . Using 
ABTS data, LL and BL groups showed signifi cantly eleva ted anti-
PG IgM levels not related to Bl. OPD data indica te LL , BL, BB, 
and BT groups have eleva ted anti-PG lgM levels not related to 
Bl . 
ELISA screening for anti-PG IgG showed LL patients as a group 
had significantly higher anti-PG IgG levels than controls (p < 
0.01) (Fig 5) . The nonparametric Kruskal-Wallis tes t showed LL, 
BL, and BB groups to be significantly higher in anti-PG IgG than 
controls (p < 0.05). Although some BT patients had elevated 
anti-PG IgG, as a group BT was not significantl y higher than 
control. 
There was not a sign ificant co rrelation between BI and anti-
PG IgG as there was for anti-PG IgM when all patients were 
analyzed . H owever, w hen only BLand LL patients were analyzed 
it appeared that a relationship existed among Bl, anti-PG IgG, 
and ENL in which anti-PG IgG increased with rising BI in ENL 
patients and remained the same or decreased sli ghtly with rising 
Bl in non-ENL patients (Table III) . Thus the effect of ENL on 
anti- PG IgG levels was opposite to the ENL effect on anti-PG 
IgM levels. 
DISCUSSION 
Our study shows that, under appropriate conditio ns , anti-PG IgM 
antibodies correlate directly with the BI. This findin g means that 
anti-PG lgM can be used to monito r disease ac tivity in leprosy 
patients . While exceptions occur (such as ENL and possible ba-
cillary or antigenic persistence) an elevated anti-PG IgM should 
alert the clinician to bacillary activity and serve as an adjunct to 
skin biopsies and slit smears. Because bacillary activity varies 
significantly from one region to another, a negative skin biopsy 
in one region does not exclude baci ll ary ac tivity in o ther regions 
of the skin, nerves , or even visceral involvement such as the liver, 
spleen , or testicles . We currently utilize slit smea rs on patients 
who are bacillary-negative by skin biopsy, but have elevated anti-
PG IgM and are proven hepatitis B antigen-nega tive. Factors 
other than Bl , ENL, and bacillary persistence, such as genetics 
[9], are likely to also affect the an tibody response to PG. N ever-
theless, from the epidemiologic vantage , the finding that anti-PG 
lgM reflects bacillary load should make it possible to evaluate 
bacillary activity within a given program or given geograph ic 
region. This ability may prove important for evaluatin g vacci-
nation or other strategies, such as the use of recombinant T - cell 
products, for leprosy control. 
Bacillary persistence is an identified problem in leprosy [1 0]. 
The reasons for bacillary persistence are currently poorly under-
stood. Subpopulations of Schwann cells or m acrophages m ay 
harbor antibiotic-sensitive bacilli although in selected individuals 
antibiotic distribution patterns, or o ther mechanisms, may be 
involved. Existing methods for monitoring bacillary persistence 
in leprosy are cumbersome. Multiple skin biopsies, slit smears, 
and even nerve biopsies sa mple only small regions and do not 
exclude bacillary activity in other areas. The degree to which an 
elevated anti-PG IgM reflects bacillary persistence in patients, 
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Table I. Relationship Among Anti-PG lgM, BI , and ENL in LL and BL Patients 
ENL No ENL 





aE lgM = 0. 140 + 0.05 1(BI)" 
aE lgM = 0.242 + 0.04 I(BI) 
55 
55 
aE IgM 0.238 + 0. 115(B I) 
aE lgM = 0.262 + 0.082(B I) 
•Slope of ENL regression line significantly different than non-ENL regression line (I' < 0.01). . 
Abbreviations: PC . phenolic glyco hptd I; Bl, bactllary mdcx; ENL, erythema nodosum leprosum: LL, lepromatous leprosy; BL. bordcrlme lepromatous leprosy; ABTS. 
2, 2 • -azin o-di (3-eth y 1-benzth.azol tne-6-sulfomc aCid); OPD. o-phcn ylened~amme. 
who by other avai lable clinical criteria are bacillary-negative, is 
still not known . The slow elimination of the insoluble glycolipid 
antigen may require introducing the term "antigenic persistence" 
as well as " bacillary persistence." An elevated anti-PG IgM could 
·ndicare both in so me instance and only antigenic persistence in ~rhers. Whether or not an elevated anti-PG IgM requires more 
agg ressive therapy w ill be determined by future relapse rates . The 
duration of treatment with multiple antibiotics vs changing to a 
single "maintenance" regime is still undecided in leprosy [11, 12). 
Multibacillary leprosy patients treated w1th antibiOtiCS probably 
never become totally bacillary-negative. This is supported by the 
ecidivistic nature of multibacillary leprosy when antibiotic ther-
: PY is discontinued as well as by the phenomenon of bacillary 
pers istence [ 10] . The persistence of M. leprae and mycobacterial 
antigens has been demonstrated in nerve biopsies from leprosy 
pa tien ts considered inactive by other criteria [13) . Thus our study 
suggests that the determination of serum anti-PG lgM levels, 
annually performed, as an adjunct to skin biopsies and skm scrap-
ings, s hould assis.t the. clinician in the decision on duration as well 
as regime of antibiOtic trea tment. Further study and sequential 
monitoring of leprosy patients IS clearly md1cated . Furthermore, 
sequential monitoring of contacts with good clinical evaluation 
and correlation should elucidate the usefulness of PG antibodies 
as a serologic screening tes t for leprosy , e.g., we already have 
detec te d a contact with an elevated anti-PG lgM . The contact 
(w ife of a BL patient) had a monon.europathy by clinical exam-
ination and nerve conduction velocity tests . A skm b1opsy was 
read as nonspecific dermatitis and slit smears were negative. This 
symptomatic contac t has been placed on Dapsone, 50 mg q.d . 
H er neuropathy will be followed clinically and by electrophysi-
ologic monitoring . Only by further study of contacts with clinical 
correla tion will we be able to determme at what stage ant1bod1es 
to PG will be able to diagnose leprosy. 
ENL, a major complication of multi bacillary leprosy, has been 
attributed to a possible Arthus hypersensitivity reaction, induced 
by immune complexes [14] . The demonstration of lgM, but not 
IgG in ENL skin biopsies [15] as well as the mh1b1t1on of IgM 
Table II. Anti-PG IgM Levels for Ridley-Jopling (R-J) 
Groups Adjusted for Effects of BI 
ABTS OPD 
No. of 
R-J Group Patients Mean aE Adjusted aE Mean aE Adjusted aE 
LL 95 0.33 0.27" 0.35 0.31 " 
BL 15 0.49 0.42" 0.45 0.41'' 
BB 5 0.24 0.31 0.47 0.52" 
BT 33 0.1 3 0. 19 0.24 0.29" 
TT 4 0.02 0. 11 0.20 0.26 
HC 8 0.03 0. 11 0.08 0.14 
NC 14 0.00 0.09 0.09 0.16 
Cone 18 0.04 0.12 0.07 0.13 
'Significantly diflcrent than controls (p < 0.05). 
Abbreviations: PC . phenolic glycolipid I; 81, bacillary index; ABTS. 2,2'-azino-
di(:>-ethyl-benzthiazoline-6-sulfonic acid); OPD, a-phenylenediamine; E, ex tinction; 
LL, lepromatous leprosy; BL, borderline lepromatous leprosy; BB, midborderlinc 
leprosy; B T, borderline tuberculoid leprosy; TT, tuberculoid leprosy; HC, house-
hold con t acts; NC, nosoco mial conracts; Cout, controls . 
synthesis by thalidomide [16], an effective treatment for ENL, 
suggest that IgM plays a major role in the pathogenesis of ENL. 
In keeping with the studies of Cho et al [17] and Andreoli et a] 
[18], our study demonstrates significantly lower anti-PG IgM 
levels in patients with ENL reaction as compared with those 
without ENL, especially in patients with very high BI. The dif-
ferences between results achieved with OPD and ABTS are most 
probably at the level of sensitivity and serum dilution. The 2 
detection systems are generally in agreement, but the slightly 
increased background with OPD did not allow the ENL effect 
to achieve statistical significance. Additional co mparison of our 
results with other laboratories is also in keeping with this inter-
pretation (unpublished observations) . Conversely, anti-PG IgG 
for ENL patients was somewhat higher than for non-ENL pa-
tients of co mparable BI (also BB and BL higher than LL) . LL and 
BL together and BL individually all showed significant differences 
in anti-PG IgG levels of ENL vs non-ENL patients of co mparable 
BI. In addition, Modlin et al [ 19,20] have shown an increase in 
putative interleukin 2 producer cells during ENL by immuno-
cytochemistry . These findings suggest that T -cell function and 
probably T -cell products are involved in the isotype switch from 
IgM to IgG and that T -cell function as well as immune co mplexes 
may be involved in ENL. The finding of opposite effects (i.e., 
decreasing anti-PG lgM and increasing anti-PG IgG) in ENL m ay 
reflect immune com plex formation of lgM antibodies and an 
increase in T-cell products required for IgG production . Further 
studies, including sequential studies are indicated to further in-
vestigate these findings. 
Overall, anti-PG IgG was significantly less pronounced than 
anti-PG IgM , in keeping with the findings of others [2,3]. How-
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Figure 5. Anti-PG lgG vs Ridley-Jopling classification, ABTS substrate 
solution, sera diluted 1 ; 20. 
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Table III. Relationship Among Anti-PG IgG, BI, and ENL in LL and BL Patients 
ENL No ENL 






~E IgG = 0.023(BI) + 0.014" 55 ~ElgG -0.005(Bl) + 0.091 ~E lgG = 0.143(Bl) + 0.0 1 0~> 11 ~ElgG -0.016(Bl) + 0.065 
LL ~E lgG = 0.01 6(Bl) + 0.008 44 ~ElgG -0.003(Bl) + 0.083 
'Slope of ENL regress ion line significantly different than non-ENL regression line (p = 0.02). 
'Slope of ENL regression line significantly different than non-ENL regression line (p = 0.0 12). 
Abbrevia1ions: PC, phenolic glycolipid I; 8/, bacillary index; ENL, erythen~> nodosum lcprosum; LL, lcpronlJtous leprosy; BL, borderline lepromatous leprosy; E. 
extinction . 
ever, since several of the BB and BL (and one BT) patients had 
very high levels of anti-PG IgG it seems less likely that the in-
ability to m ount an IgG response to PG is an inherent property 
of PG. More likely it has to do with patient characteristics and 
requirements for isotype class switching. T -cell products, pos-
sibly including y-interferon and other factors involved in B-cell 
maturation have been identified [21 -23). T-cell products, includ-
ing interleukin 2 and y-interferon, have been found deficient in 
some leprosy patients, particularly toward the lepromatous end 
of the spectrum (24,25]. Cells active in suppress in g mitogenic 
(26) and specific antigen (27] responses have been described in LL 
and subclinical leprosy infections. At this time, littl e is known 
on the nature and diversity of B-ccll differentiation factors in 
humans. Studies in the mouse already indicate a va riety of dif-
ferent B-cell differentiation factors [21] . Thus, the inability of 
many LL patients to mount an anti-PG IgG response may be 
related to deficiencies of T -cell products required for iso type 
switchin g. Alternatively, suppressor mechanisms and active in-
hibition of the isotype switch may be involved in the pathogenesis 
of leprosy infections. 
We tlwnk Mr . Pl1ilip Pepper and tile National Ha11se11 's Disease Co11traC1 Care 
Pro,~ram for t!Jeir support. 
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